peptide hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-04. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
White blood cells defend against infections and are involved in the inflammatory response. A high white blood cell count, which is called leukocytosis, often occurs in infections, inflammation, and states of physiologic stress. It can also be caused by diseases that involve abnormal production of blood cells, such as myeloproliferative and lymphoproliferative disorders. A decreased white blood cell count, termed leukopenia, can lead to an increased risk of acquiring infections, and occurs in treatments like chemotherapy and radiation therapy and many conditions that inhibit the production of blood cells. Sepsis is associated with both leukocytosis and leukopenia. The total white blood cell count is usually reported in cells per microlitre of blood (/μL) or 109 cells per litre (× 109/L). In the white blood cell differential, the different types of white blood cells are identified and counted. The results are reported as a percentage and as an absolute number per unit volume. Five types of white blood cells—neutrophils, lymphocytes, monocytes, eosinophils, and basophils—are typically measured. Some instruments report the number of immature granulocytes, which is a classification consisting of precursors of neutrophils; specifically, promyelocytes, myelocytes and metamyelocytes. Other cell types are reported if they are identified in the manual differential. Differential results are useful in diagnosing and monitoring many medical conditions.
Theodor Curtius was born in Duisburg in the Ruhr area in Germany. He studied chemistry with Robert Bunsen at Heidelberg University and with Hermann Kolbe at Leipzig University. He received his doctorate in 1882 at Leipzig University. After working from 1884 to 1886 for Adolf von Baeyer at the Ludwig-Maximilians-Universität München, Curtius became the director of the analytical chemistry department at University of Erlangen until 1889. Then he accepted the chair in Chemistry at Kiel University, where he remained very productive. In line with this success, Curtius was appointed Geheimer Regierungsrat (Privy Councillor) in 1895. After a one-year appointment as the successor of the famous August Kekulé at the University of Bonn in 1897, Curtius succeeded Victor Meyer as Professor of Chemistry at his old university at Heidelberg University in 1898, where he remained until his retirement in 1926. He was awarded honorary membership of the Manchester Literary and Philosophical Society in 1892 and was succeeded by Karl Freudenberg, who wrote Curtius' biography in 1962.[1] In his free time, he also composed music, sang in concerts, and was an active mountaineer. In 1894, he founded the Kiel section of the Association of German and Austrian Alpinists, which he personally supported with gifts. In his Munich period, he became a close friend of the alpinist guide Christian Klucker, with whom he made mountaineering hikes for many years thereafter. Theodor Curtius died in Heidelberg on 8 February 1928.
=== Analogues === Analogues of SR-17018, which is also known as 5,6-dichlorodesmethylchlorphine, include brorphine, chlorphine, SR-14968 (5,6-dichlorobrorphine), SR-14969, SR-15098, SR-15099, SR-16435, Muzepan1, and Muzepan2, among others.
Sources: en.wikipedia.org
Algae can be used as indicator organisms to monitor pollution in various aquatic systems. In many cases, algal metabolism is sensitive to various pollutants. Due to this, the species composition of algal populations may shift in the presence of chemical pollutants. To detect these changes, algae can be sampled from the environment and maintained in laboratories with relative ease. Some indicator algae in the phylum Dinoflagellata, such as Noctiluca scintillans (sea sparkles) and the genus Pyrocystis, exhibit bioluminescence via luciferin catalyzed by luciferase, just like fireflies. Their glow is believed to have a startle effect stunning predators, with a secondary benefit of the burglar-alarm hypothesis where the flashes attract higher-order predators that prey on algae grazers. On the basis of their habitat, algae can be categorized as: aquatic (planktonic, benthic, marine, freshwater, lentic, lotic), terrestrial, aerial (subaerial), lithophytic, halophytic (or euryhaline), psammon, thermophilic, cryophilic, epibiont (epiphytic, epizoic), endosymbiont (endophytic, endozoic), parasitic, calcifilic or lichenic (phycobiont).
Cale Hooker (born 13 October 1988) is a former professional Australian rules footballer, who played for the Essendon Football Club in the Australian Football League (AFL). Hooker graduated from Applecross Senior High School and played for East Fremantle in the WAFL. Hooker was drafted by the Essendon Football Club with pick 54 in the 2007 national draft and made his debut against the Western Bulldogs in round 21, 2008. In 2009 and 2010 Hooker established himself as one of the club's key-position defenders. In 2011 Hooker made a good start to the season but tore a hamstring in round 13 and played only one further game for the season. During the trade period after the 2012 season Essendon contemplated trading Hooker to the West Coast Eagles. However, Hooker, who had a year to run on his contract, declined to be traded. In 2014 Hooker was Essendon's most reliable backman, coming second in the W.S. Crichton Medal and winning All-Australian selection for the first time. In 2015 Hooker was elevated to Essendon's Leadership Group. He started the year in defence but was switched to the forward line halfway through the season. He became a useful goal scorer and finished the season with 21 goals. He was awarded the W. S. Crichton Medal as Essendon's best and fairest. Hooker is noted for his marking ability and took in excess of 150 marks in each of 2013, 2014 and 2015. Hooker, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season.
This can be done with a diverse training set including many types of ligands and receptors to produce a less accurate but more general "global" model or a more restricted set of ligands and receptors to produce a more accurate but less general "local" model.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.